OncoMethylome Sciences grants Commercial License to LabCorp for MGMT Methylation Testing
MGMT methylation has been shown to be a common event in many cancers and predictive of response to some cancer therapies. For example, MGMT methylation status has been shown to be a promising potential predictor of response to alkylating agent-based chemotherapies used to treat patients with malignant brain tumors, and therefore is of interest to oncologists who treat such patients. LabCorp plans to determine MGMT methylation status using Methylation-Specific PCR technology licensed from OncoMethylome Sciences.
Because of the potential for broader applications of this oncology marker, the evaluation of MGMT methylation is being integrated into numerous international clinical trials for patients with brain cancer and other cancers. The trials are conducted by organizations such as the U.S.-based Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).
Most read news
Topics
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.